EWM
BIIB icon

Elevatus Welath Management’s Biogen BIIB Stock Holding History

Elevatus Welath Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,555
Closed -$400K – 95
2023
Q3 		$400K Hold
1,555
– – 0.36% 43
2023
Q2 		$443K Buy
+1,555
New +$463K 0.31% 37

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Elevatus Welath Management's BIIB Position: Q4 2023 in Review

Elevatus Welath Management sold out of Biogen (BIIB) in Q4 2023, closing a stake of 1,555 shares — an estimated $400K sold.

Elevatus Welath Management first reported a position in BIIB in Q2 2023 and held it in 2 quarters. The position peaked at $443K in Q2 2023. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

  • Elevatus Welath Management reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
  • Elevatus Welath Management sold 1,555 Biogen shares in Q4 2023, an estimated $400K.
  • Elevatus Welath Management first reported a position in Biogen in Q2 2023 and held it in 2 quarters.
  • Elevatus Welath Management's Biogen position peaked at $443K in Q2 2023.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on Elevatus Welath Management's 13F filing for Q4 2023, filed 12 Feb 2024.